Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Pathophysiology of SLE
- Biomarkers in SLE
- Biomarker Definition
- Biomarkers and Surrogate End Points
- Necessary Attributes of an SLE Biomarker
- Value of a Biomarker for SLE
- Current Status of SLE Biomarkers
- Overview
- Genetic Markers of Susceptibility, Organ Involvement, or Severity
- Diagnostic Markers
- Markers of Disease Activity
- Disease-Activity Indices and End Points in SLE Clinical Trials
- Promising and Possible SLE Biomarkers
- Type I Interferon
- sVCAM-1
- CD27 High Plasma Cells
- Soluble IL-2 Receptor (Soluble CD25)
- BLyS
- Market Implications
- Outlook
Tables
- 1. Clinical Manifestations of Systemic Lupus Erythematosus
- 2. Select Promising Genetic Biomarkers in SLE
- 3. American College of Rheumatology Classification Criteria for the
Diagnosis of Systemic Lupus Erythematosus
- 4. Select Disease-Activity Indices in SLE and Their Advantages and
Disadvantages
Figures
- 1. Pathogenesis of Systemic Lupus Erythematosus
- 2. Diagnosed Prevalent Cases of Systemic Lupus Erythematosus, 2005
- 3. Pipeline of Systemic Lupus Erythematosus Therapies
|
Related Report
|
View Cart
